An Ad Blitz That Really Worked?

Biotech Industry Gets a Big Win on Biologics

By Kate Ackley
Roll Call Staff

July 15, 2009, 12 a.m.

A highly targeted lobbying and advertising campaign by the biotechnology and pharmaceutical industries paid off this week when a Senate panel writing health care reform legislation swung their way on the issue of biologic drugs.

Most Popular
Most E-Mailed

CRS Report Shows Most Bills Subject to Cloture Pass
Sarah Palin? Frankly, My Dear, I Don’t Give a Damn
Lugar’s Wife Arrested for DUI

Plastic Surgeons Pressure Senate to Nip New Tax
Senate Phones Disrupted by Deluge of Calls
Lugar’s Wife Arrested for DUI

Committee
Insider
Policy
Briefings
Mission
Ahead
10 Staffers
to Know

Schumer Advocates for Many on Panel

Nov. 16, 12 a.m.

As Senate Majority Leader, Lyndon Johnson once said of the Joint Economic Committee, “It’s as useless as tits on a bull.” But as that panel’s chairman during the 110th Congress, Sen. Charles Schumer (D-N.Y.) seized the opportunity to elevate the traditionally low-profile post to the forefront of shaping policy. Read Full Article